)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
EyePoint Pharmaceuticals (EYPT) investor relations material
EyePoint Pharmaceuticals Stifel 2025 Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Stifel 2025 Healthcare Conference summary12 Nov, 2025
Clinical development progress
Phase III trials for wet AMD (LUGANO and LUCIA) are fully enrolled, with top-line data expected mid-2026 and a second trial to follow soon after.
DME phase III trials (COMO and CAPRI) will begin dosing in Q1 2026, randomizing 240 patients each, with top-line readouts anticipated in Q4 2027.
Four prior trials (one phase I, three phase II) showed strong efficacy and safety in over 190 patients, with no ocular or systemic SAEs.
DuraCert/Durasert E technology is proven, with four FDA-approved products and controlled, sustained drug delivery.
Pipeline includes preclinical asset EYP2301 (ResprotaFib), a TIE-2 agonist for retinal diseases, with Phase 3 FPI anticipated in Q1 2026.
Technology and mechanism of action
Duravyu, a DuraCert E product, delivers 94% drug and 6% matrix, with no PLGA or PEG, and provides sustained release for at least six months.
Vorolanib, the active drug, blocks all VEGF receptors and inflammation via JAK1, offering multi-MOA benefits including anti-VEGF, anti-PDGF, and anti-IL-6 effects.
Immediate drug levels are achieved in the choroid, and the insert dissolves without leaving free-floating particles.
The injector system is preloaded, sterile, and can be stored at room temperature, reducing logistical burdens.
DURAVYU is the only TKI in development for DME, with a dual mechanism targeting both VEGF and IL-6.
Clinical trial design and results
Wet AMD phase III trials are non-inferiority studies using on-label Eylea as control, with all patients loaded with Eylea monthly.
DME phase II Verona trial showed Duravyu provided faster and greater vision improvement and OCT reduction compared to Eylea, attributed to IL-6 blockade.
Over 70% of patients in the 2.7 mg arm were rescue-free, with significant anatomical normalization and sustained effects for 24 weeks after a single dose.
Dose-dependent reduction in macular leakage and improved BCVA were observed, with comparable efficacy to monthly anti-VEGF plus anti-IL-6 regimens but with fewer injections.
Rescue criteria in wet AMD phase III is loss of five letters from best on study with 75 microns of new fluid.
What drives market share if only non-inferior?
Why different Duravyu dosing in DME vs. AMD?
Northbridge capacity vs. projected commercial demand?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next EyePoint Pharmaceuticals earnings date
Q4 20252 Mar, 2026
Next EyePoint Pharmaceuticals earnings date
Q4 20252 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic therapies. The company specializes in sustained-release drug delivery technologies to address serious eye diseases, including conditions affecting the retina and anterior segment of the eye. EyePoint’s product portfolio includes treatments for inflammation and other ocular disorders, and it supports both commercialized products and clinical development programs. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage